Carbohydrate recognition has been shown to be involved in various biological processes and should be useful for an active-targeting DDS (Drug Delivery System). However, carbohydrate recognition has not yet been applied to targeting delivery to tissues or lesions, except for a galactose ligand for the asialoglycoprotein receptor expressed in liver. 2, 3) Also, there are disadvantages for targeting delivery using galactose derivatives. For example, in the case of hepatic tumors, anti-tumor drugs modified with galactose derivatives could not be delivered selectively to tumor sites because the asialoglycoprotein receptor is expressed throughout the whole liver containing non-tumor sites. Therefore, it is not a tissue-specific but a lesion-specific active-targeting DDS that is required.
Also, there are disadvantages for targeting delivery using galactose derivatives. For example, in the case of hepatic tumors, anti-tumor drugs modified with galactose derivatives could not be delivered selectively to tumor sites because the asialoglycoprotein receptor is expressed throughout the whole liver containing non-tumor sites. Therefore, it is not a tissue-specific but a lesion-specific active-targeting DDS that is required.
Recently, attention has been directed to cell adhesion molecules called selectins which are involved in various aspects of immune cell trafficking. We have focused on the interaction between E-selectin and sialyl Lewis X (SLe X , Neu5Aca2→3Galb1→4(Fuca1→3)GlcNAc).
4)
E-selectin is expressed on the endothelial cells stimulated by cytokines, such as IL-1b or TNF-a at inflammatory sites, and plays an important role in the transport of neutrophils to inflammatory sites. The tetrasaccharide SLe X is distributed on the surface of neutrophils, and has been shown to be a ligand recognized by E-selectin. As the interaction between SLe X and E-selectin is essential for the initial stage of neutrophil infiltration of the inflammatory site, SLe X and its derivatives, which block this interaction, should be useful as new anti-inflammatory agents. 5) SLe X and its derivatives may be effective homing devices for active-targeting DDS to inflammatory lesions because Eselectin is only expressed on such lesions. Thus, DDS using SLe X derivatives as homing devices may be effective for drug delivery not to normal tissue but directly to inflammatory lesions. However, to the best of our knowledge, there have been no examples using SLe X as a homing device for DDS. The reason may be that the affinity of carbohydrate for their protein has been shown to be relatively weak and carbohydrates are generally sensitive to glycosidase in vivo. Moreover, oligosacharides such as SLe X should be rapidly filtered at the glomerulus because of its high hydrophilicity and low molecular weight.
6) One way to solve these problems would be to support SLe X on a macromolecule 7) which would stabilize the sugar moiety and enhance multivalent interaction of SLe X with E-selectin expressed at the inflammatory lesion. In our research laboratories, we have studied DDS using liposomes, 3) polypeptides, 8) or polysaccharides 9, 10) as carriers and have already reported that some polysaccharides of molecular size above 70 kDa, such as carboxymethylchitosan (CMCht) 9) and carboxymethylpullulan (CMPul), 10) are useful as carriers for a passive-targeting DDS to tumors. The doxorubicin-CMPul conjugate dramatically enhances the therapeutic index of the antitumor effects. 10) This type of conjugate is highly biocompatible and is retained in the circulating blood. 11) Moreover, these conjugates have been found to accumulate in tissues with enhanced vascular permeability such as tumor and inflammatory sites, where E-selectin is expressed, and thus, a synergic effect can be expected between SLe X and polysaccharides. These findings prompted us to synthesize SLe X -polysaccharide (CMCht and CMPul) conjugates and evaluate their usefulness as an active-targeting device for delivery to inflammatory lesions.
The sulfated polysaccharide heparin, or N-desulfated heparin (DSH), is an important drug used to prevent cardiovascular diseases and it has been reported to have many unique biological activities.
12) Since these polysaccharides are also expected to be useful as drug carriers of DDS, because of their price and ease of acquisition, we synthesized a conjugate of SLe X with N-desulfated heparin (DSH) and evaluated its pharmacokinetics. We also synthesized SLN(Neu5Aca2→Galb1→4Glc-NAc)-polysaccharide conjugates as the negative control. SLN is a trisaccharide without the fucose moiety of SLe X and it has been reported not to support E-selectin-mediated adhesion.
13)
Synthesis of SLe X -Polysaccharide Conjugates It was planned to prepare a SLe X -CMCht conjugate (1) by N-alkylation using the amino group of CMCht and the bromo group of 6. The synthesis of SLe X -bromide (6) 14) is described in Chart 1. The bromo alcohol (8) was prepared in two steps from commercially available hexaethyleneglycol [i) MsCl/ Py., ii) LiBr/2-butanone, 40%]. 2-Methyl-4,5-(3,4,6-tri-Oacetyl-2-deoxy-a-D-glucopyrano)-2-oxazoline (9), 15) which is readily available from N-acetyl-D-glucosamine, was reacted with bromo alcohol (8) in the presence of TMSOTf to give a b-glycoside (10, 80%), which was converted to the glycosyl acceptor (11) in two steps [i) NaOMe/MeOH, ii) PhCH(OMe) 2 /CSA/DMF (65%)]. Compound 11 was glycosylated with thioglycoside (12) 16) using Me 2 SSMe · OTf 17) in CH 2 Cl 2 at 0°C to afford the disaccharide 13, as a mixture of a-and b-glycosides (95%, a : bϭ15 : 1, separation of the aand b-glycosides was difficult). By means of the regioselective ring opening reaction of benzylidene acetal using NaBH 3 CN-HCl, 18) 13 was converted to the 6-O-benzyl ether with the 4-hydroxy unsubstituted compound 14 (77%). However, NaBH 3 CN is a hazardous chemical and difficult to use safely on a large scale, so we investigated the ring opening reaction using alkylsilane derivatives 19) in place of NaBH 3 CN as a reducing reagent and found Et 3 SiH-TfOH to be useful (83%). On the other hand, when PhBCl 2 was used instead of TfOH, 4,6-O-benzylidene acetal was converted to the corresponding 4-O-benzyl ether with the 6-hydroxy unsubstituted compound in excellent yield, and regioselectivity was complete. Our improved method has proved to be useful 20) not only for this substrate but other carbohydrates having the 4,6-O-benzylidene ring and therefore should be useful for the synthesis of various oligosaccharides.
Glycosylation of 14 with sialyl-galactose imidate (15) 21) in the presence of BF 3 · OEt 2 led to the tetrasaccharide 16 (61%), which was hydrogenated with 10% Pd-C in MeOH to afford 17 (73%) and 18 (16%). When this hydrogenation was carried out for a long period (over ca. 12 h), 18 was obtained as a major product. Deacylation of 17 followed by saponification of the methyl ester group gave the bromide (6, 93%).
CMCht was prepared from chitin according to a known procedure, 9) and had the following characteristics: M.W., about 100 kDa; degrees of substitution (ds) of N-acetyl group, 0.47; ds of amino group, 0.45; ds of carboxymethyl group, 0.7.
By means of N-alkylation of CMCht with bromide (6) in 0.5% NaHCO 3 -H 2 O for 160 h at 60°C, a SLe X -CMCht conjugate (1) (1) (2) (3) and monovalent SLe X (7) were compared with respect to their accumulation in inflammatory lesions (dose: 1 mg/mg, i.v.). The plasma concentration of monovalent SLe X (7) decreased rapidly and could not be detected one hour later, and the concentration in the inflamed ear remained low. On the other hand, SLe X -polysaccharide conjugates (1) (2) (3) were retained in blood circulation as expected, and subsequent maked enhancement of accumulation in the targeted lesion was observed. The AUC (area under the blood concentration-time curve) 0-24 h of macromolecules 1, 2, and 3 at the inflammatory lesion was about 60-, 300-, and 30-fold higher than that of the monovalent SLe X (7), respectively. The AUC 0-24 h of 3 in plasma was lower than that of 1 or 2. Thus, compound 3 underwent glomerular filtration before arriving at the inflammatory lesion faster than 1 or 2, and the accumuation of 3 in the inflammatory lesion was considered to be lower. Reduced accumulation of CMCht conjugate 1 compared with 2 was due to the degradation of CMCht by lysozyme in vivo. These findings show that supporting SLe X on polysaccharide is an effective way to enhance accumulation in inflammatory lesions.
Secondly, the accumulation of SLe X -polysaccharide conjugates (1, 2) in inflammatory lesions was compared with that of SLN-polysaccharide conjugates (4, 5). Compound 1 showed a 2-fold higher accumulation in the inflammatory lesion than 3, and 2 showed a 2.5-fold higher accumulation than 4. These differences in distribution are thought to be due to differences in the ability to bind to E-selectin.
These results indicate that the interaction between SLe X and E-selectin could be applied to targeting DDS, and SLe X -polysaccharide conjugates was useful as drug carriers to inflammatory lesions. SLe X -CMPul (2) showed a 16-fold higher accumulation in the spleen than SLN-CMPul (4). Although the reason is not clear, the accumulation dose not involve E-selectin because it was observed in non-treated normal mice. These are interesting results because the pharmacokinetics of macromolecules such as CMPul change markedly simply following changes in the sugar residues in the macromolecule.
In conclusion, we established a method of synthesizing SLe X -polysaccharide conjugates, and these conjugates have been shown to be a useful novel system for active-targeting DDS to inflammatory lesions. In the future, we plan to introduce an anti-inflammatory agent to our system and evaluate the subsequent therapeutic effects.
Experimental
All melting points were determined on a Yanagimoto micromelting point apparatus and were not corrected.
1 H-NMR spectra were measured on a Varian VXR-500S (500 MHz) spectrometer, unless otherwise specified. Chemical shifts (d) are given in ppm relative to tetramethylsilane as an internal standard. IR spectra were measured on a Shimadzu FT-IR-4300. Optical rotations were determined with a Perkin-Elmer 430 polarimeter. FAB-Mass spectra were recorded on a Hitachi M-90 instrument.
17-Bromo-3,6,9,12,15-pentaoxa-1-heptadecanol (8) To a stirred solution of hexaethyleneglycol (23.8 g, 84.3 mmol) in CH 2 Cl 2 (200 ml) were added Et 3 N (14.1 ml, 101 mmol), and methanesulfonylchloride (6.52 ml, 84.3 mmol) at 0°C. After being stirred at 0°C for 1 h, the mixture was diluted with CH 2 Cl 2 , washed with 2% aqueous citric acid and saturated aqueous NaHCO 3 , dried over MgSO 4 and concentrated in vacuo.
The crude mesylate was dissolved in 2-butanone (300 ml), and then LiBr (36.6 g, 422 mmol) was added . After stirring for 1 h under reflux, the mixture was diluted with CH 2 Cl 2 , washed with saturated brine, dried over MgSO 4 and concentrated in vacuo. The crude product was purified by silica gel column chromatography [SiO 2 500 g, CH 2 Cl 2 : MeOHϭ20 : 1] to give 8 (11.8 g, 40%) as a colorless oil. IR (CHCl 3 ) cm 3.48 (2H, t, Jϭ6.3 Hz), m), m), m), 3.82 (2H, t, Jϭ6.3 Hz) .
17-Bromo-3,6,9,12,15-pentaoxaheptadecyl 2-Acetamido-3,4,6-tri-Oacetyl-2-deoxy-b b-D-glucopyranoside (10) To a stirrred mixture of 9 15) (1.85 g, 5.62 mmol), 8 (1.56 g, 4.52 mmol) and powdered molecular sieve 4 Å (MS4A, 1.2 g) in 1,2-dichloroethane (12 ml), was added trimethylsilyl trifluomethanesulfonate (835 ml, 4.30 mmol) at room temperature, and the stirring was continued for 1.5 h at 50°C. The mixture was cooled to room temperature, and then triethylamine (1.40 ml, 10.0 mmol) was added. After stirring for 10 min at room temperature, the resultant mixture was filtered, and the filtrate poured into CH 2 Cl 2 . The organic phase was washed with water, dried over MgSO 4 and concentrated in vacuo. 17-Bromo-3,6,9,12,15-pentaoxaheptadecyl 2-Acetamido-4,6-O-benzylidene-2-deoxy-b b-D-glucopyranoside (11) To a stirred solution of 10 (13.0 g, 19.3 mmol) in MeOH (30 ml) at room temperature was added 28% sodium methoxide in MeOH (0.3 ml) and the stirring was continued at room temperature for 30 min. The reaction mixture was neutralized with Dowex 50Wϫ8 (H ϩ form) and filtered. The filtrate was concentrated in vacuo. The residue was dissolved in N,NЈ-dimethylformamide (50 ml), and then were added benzaldehyde dimethyl acetal (10.9 ml), and 10-camphor sulfonic acid (125 mg). After stirring for 3 h at 55°C under reduced pressure (45 mmHg), the mixture was neutralized with anion exchange resin (AG-1(OH Ϫ )) and filtered. The filtrate was concentrated in vacuo, and the crude product was purified by silica gel column chromatography (SiO 2 150 g, toluene : acetone : MeOHϭ20 : 30 : 1) to give 11 (7.57 
To a solution of 11 (636 mg, 1.00 mmol) and 12 15) (697 mg, 1.50 mmol) in CH 2 Cl 2 (20 ml), was added powdered MS4A (10 g), and the mixture was stirred for 2 h at room temperature. Dimethyl(methylthio)sulfonium triflate (DMTST, 1.16 g, 4.50 mmol) was added to the stirred mixture at 0°C, and stirring was continued for 30 min at 0°C. MeOH (2 ml), and Et 3 N (1 ml) were added, and then the resultant mixture was filtered. 3.45 (2H, t, Jϭ6.3 Hz), m), 3.56 (1H, m, m), m), 3.78 (2H, t, Jϭ6.3 Hz), 3.94 (1H, dd, Jϭ10.3, 2.7 Hz, 4.04 (1H, dd, Jϭ10.3, 3.7 Hz, 4.11 (1H, q, Jϭ6.3 Hz, 4.22 (1H, dd, Jϭ9.5, 9.5 Hz, 4.33 (1H, dd, Jϭ10.5, 4.9 Hz, 4.57, 4.71, 4.79, 4.91 (each 1H, d, Jϭ11.7 Hz), 4.70, 4.78 (each 1H, d, Jϭ11.5 Hz) (1 g) was placed in a 20 ml flask, and dried at 140°C over 4 h under vacuum (ca. 0.1 mmHg). After cooling to room temperature, 13 (210 mg, 0.20 mmol), and CH 2 Cl 2 (3.5 ml) were added. After stirring for 1 h at room temperature, the mixture was cooled to Ϫ78°C, and then Et 3 SiH (112 ml, 0.70 mmol) and TfOH (46 ml, 0.60 mmol) were added, successively. After stirring for 1 h at Ϫ78°C, Et 3 N (1 ml) and MeOH (1 ml) were added, successively, and the mixture was diluted with CHCl 3 , washed with aqueous NaHCO 3 , dried over MgSO 4 , filtered and concentrated. The crude product was purified by a silica gel column (20 g, CHCl 3 14 (1H, d, Jϭ7.8 Hz, NH), m 
To a solution of 14 (1.07 g, 1.01 mmol) and 15 19) (400 mg, 0.406 mmol) in CH 2 Cl 2 (6 ml), was added powdered MS4A (2 g), and the mixture was stirred for 2 h at room temperature. To the stirred mixture, BF 3 · OEt 2 (100 ml, 0.812 mmol) was added at 0°C, and the stirring was continued for 2 h at 0°C. The reaction mixture was filtered, and the filtrate was diluted with CH 2 Cl 2 , washed with saturated aqueous NaHCO 3 
To a solution of 16 (200 mg) in tetrahydrofuran (15 ml) was added Pd-C (10%, 100 mg), and then hydrogenation was carried out for 24 h at room temperature. The mixture was filtered, and the filtrate was concentrated in vacuo. The crude product was purified by preparative thin-layer chromatography (CH 2 Cl 2 : MeOHϭ8 : 1) to give 17 (118 mg, 73%), and 18 (25 mg, 16% 
To a solution of 17 (220 mg) in MeOH (5.0 ml) was added 3% sodium methoxide (200 ml), and the mixture was stirred for 30 min at room temperature. The reaction mixture was neutralized with Dowex 50Wϫ8 (H ϩ ), the mixture filtered, and the filtrate concentrated in vacuo.
The residue was dissolved in 0.1 N NaOH aq. (3.0 ml), and then the mixture was stirred for 10 min at room temperature. The reaction mixture was neutralized with Dowex 50Wϫ8 (H ϩ ), the mixture filtered, and the filtrate concentrated in vacuo.
The crude product was chromatographed on a column of Sephadex MeOH) (20 mg) . After stirring for 160 h at 60°C, the reaction mixture was poured into 99.5% EtOH (35 ml) and the entire mixture centrifuged. The precipitate was successively washed with 95% EtOH, acetone, and Et 2 O, then dried in vacuo to give almost pure 1. After dissolving the product in H 2 O (10 ml), the solution was dialyzed using membrane tubing (M.W. cut off; 12000-13000, Spectra) against deionized H 2 O (10000 ml) for 12 h, and lyophilized to give a SLe X -CMCht conjugate (1, 47 mg) .
It was confirmed by a GPC analysis that low M.W. molecules derived from 6 were completely excluded from 1, and the structure of 1 was confirmed by 1 H-NMR. (1H, dd, Jϭ12.4, 2.7 Hz, H-9 of Sia), 4.36, 4.48, 4.61 (each 1H, d, Jϭ12.0 Hz), 4.67 (1H, dd, Jϭ10.0, 3.7 Hz, 4.44, 4.58, 4.70, 4.75, 4.77, 4.81 (each 1H, d, Jϭ12. 5.04 (1H, d, Jϭ3.7 Hz, 5.07 (1H, d, Jϭ10.3 Hz, NH), 5.22 (1H, d, Jϭ3.7 Hz, 5.37 (1H, dd, Jϭ9.3, 2.7 Hz, 5.59 (1H, ddd, Jϭ9.3, 5.6, 2.7 Hz, 6.25 (1H, br.s, NH), m), 7.50 (1H, m), 7.97 (2H, m) . Anal. Calcd for C 91 H 117 N 5 O 35 · H 2 O: C, 58.79; H, 6.45; N, 3.76. Found: C, 58.50; H, 6.46; N, 3.69 .
17-
17-Amino-3,6,9,12,15-pentaoxaheptadecyl O-(methyl 5-acetamido-4,7,8,9-tetra-O-acetyl-3,5-dideoxy-D-glycero-a a-D-galacto-2-nonulopyra- 58 (1H, dd, Jϭ12.4, 4.6 Hz, 3.22 (1H, ddd, Jϭ13.7, 10.0, 5.1 Hz), 3.22 (1H, ddd, Jϭ13.7, 6.1, 4.6 Hz), 3.42 (1H, m), m), 3.74 (3H, s), 3.79 (5H, m), 3.85 (1H, m), 3.89 (1H, dd, Jϭ12.0, 4.9 Hz, H-6 of GlcNAc), 3.95 (1H, dd, Jϭ10.5, 10.5 Hz, m), 4.15 (1H, dd, Jϭ10.5, 8.5 Hz), 4.41 (1H, dd, Jϭ12.7, 2.9 Hz, O: C, 49.92; H, 6.45; N, 2.77; Cl, 2.34. Found: C, 49.88; H, 6.58; N, 3.08; Cl, 2.08 .
17-Amino-3,6,9,12,15-pentaoxaheptadecyl O-(5-acetamido-3,5-dideoxy-
To a solution of 20 (185 mg, 0.100 mmol) in MeOH (4 ml) was added 28% sodium methoxide (400 ml), and the mixture was stirred for 30 min at room temperature. The reaction mixture was neutralized with Dowex 50Wϫ8 (H ϩ ), the mixture was filtered, and then the filtrate concentrated in vacuo.
The residue was dissolved in a solution of 0.1 N aq. NaOH (4 ml) and 1,4-dioxane (2 ml), and then the mixture was stirred for 10 min at room temperature. The reaction mixture was neutralized with Dowex 50Wϫ8 (H ϩ ), the mixture was filtered, and then the filtrate concentrated in vacuo.
The crude product was chromatographed on a column of Sephadex MeOH) 
Compound 22 (6 mg, 5.54 mmol) was dissolved in 20 mM N-succinimidyl propionate-MeOH solution (560 ml, 11.2 mmol), and then 0.1 M N-methyl morpholine-MeOH solution (168 ml, 16.8 mmol) was added. After stirring for 12 h at room temperature, the reaction mixture was concentrated. The residue was dissolved in H 2 O (3 ml), and the solution was treated with Dowex 50Wϫ8 (H ϩ form). The resultant solution was filtrated, and the filtrate concentrated. The crude product was purified by silica gel column chromatography (SiO 2 1 g, CH 2 Cl 2 : MeOH : H 2 Oϭ 6 : 4 : 1), and gel filtration chromatography 20 g, MeOH) to give 7 (5 mg, 79%) , 7.31; N, 3.55. Found: C, 46.32; H, 7.51; N, 3.40 .
Synthesis of a SLe X -CMPul Conjugate (2) To a solution of CMPul (50 mg) in H 2 O (2 ml) were added N,NЈ-dimethyl formamide (2 ml), 21 (184 mg, 0.124 mmol) and 2-ethoxy-1-ethoxycarbonyl-1,2-dihyroquinoline (EEDQ, 610 mg). After stirring for 160 h at 40°C, the reaction mixture was concentrated. The residue was dissolved in 1 N NaOH (7 ml), and the mixture was stirred for 12 h at room temperature. The resultant mixture was poured into 99.5% EtOH (35 ml) and the entire mixture centrifuged. The precipitate was successively washed with 95% EtOH, acetone, and Et 2 O, and dried in vacuo to give almost pure 2. After dissolving the product in H 2 O (10 ml), the solution was dialyzed using membrane tubing (M.W. cut off: 12000-13000 Spectra) against deionized H 2 O (10000 ml) for 12 h, and lyophilized to give a SLe X -CMPul conjugate (2, 57 mg). It was confirmed by GPC Analysis that low M.W. molecules derived from 21, were completely excluded from 2, and the structure of 2 was confirmed by 1 H-NMR. Synthesis of a SLe X -DSH Conjugate (3) To a solution of DSH (300 mg, M.W.: 40 kDa, Sigma Co. Ltd) in H 2 O (20 ml) was added NaBH 4 (100 mg). After stirring for 19 h at room temperature, the solution was adjusted to pH 5.0 with AcOH at 0°C. After stirring for 5 min at 0°C, the solution was adjusted to pH 8.5 with 1 N NaOH at room temperature, and then the reaction mixture was poured into 99.5% EtOH (35 ml) and the entire mixture was centrifuged. The precipitate was successively washed with 95% EtOH, acetone, and Et 2 O, and dried in vacuo to give a DSH derivative which was reduced the terminal hemiacetal group (278 mg).
To a solution of the DSH derivative (40 mg) in 0.5% aq. NaHCO 3 (3 ml) were added 6 (276 mg, 0.24 mmol), and powdered NaHCO 3 (20 mg) . After stirring for 160 h at 60°C, the reaction mixture was poured into 99.5% EtOH (35 ml) and the entire mixture was centrifuged. The precipitate was successively washed with 95% EtOH, acetone, and Et 2 O, and dried in vacuo to give almost pure 3. After dissolving the product in H 2 O (10 ml), the solution was dialyzed using membrane tubing (M.W. cut off: 12000-13000 Spectra) against deionized H 2 O (10000 ml) for 12 h, and lyophilized to give a SLe X -DSH conjugate (3, 47 mg) . It was confirmed by a GPC analysis that low M.W. molecules derived from 6, were completely excluded from 3, and the structure of 3 was confirmed by (240 mg, 0.377 mmol) in N,NЈ-dimethylformamide (3 ml) were added BaO (127 mg, 0.754 mmol), Ba(OH) 2 · 8H 2 O (24 mg, 0.0754 mmol) and benzyl bromide (90 ml). After stirring for 12 h at 55°C, MeOH (3 ml) and 28% NaOMe-MeOH (150 ml) were added and the stirring was contined for 20 min. The mixture was diluted with CH 2 Cl 2 , washed with saturated brine, dried over MgSO 4 and concentrated in vacuo. 
